TP-3654 is currently being evaluated in a Phase 1/2, multicenter, dose-escalation, open-label trial to assess safety, tolerability, pharmacokinetics, and pharmacodynamics in patients with intermediate or high-risk primary or secondary myelofibrosis.
The company will provide free Diagnostics Service- X-ray Tele Radiology Services in District Hospitals / Sub-district Hospitals / Community Health Centers in the State of Tripura.
The company has posted net profit of Rs.39.71 crores for the Financial Year ended March 31, 2022.
Steinberg brings nearly three decades of experience in biopharmaceutical equity research to Prolacta's executive team.
The company has posted net profit of Rs.165.66 crores for the Financial Year ended March 31, 2022
Cloud-native Alissa data analysis SaaS platform empowers clinical labs and researchers to scale operations with parallel analysis of genomic data
The Innopack confex is a perfect platform for exhibitors to demonstrate their latest developments in the fields of pharmaceutical packaging, labelling, drug delivery device design and engineering.
82.5% of patients treated at 10mg dose of obicetrapib achieved LDL-c target of <70 mg/dL, compared to 20% of patients treated with placebo
The company has posted net loss of Rs. 67.65 crores for the Financial Year ended March 31, 2022
Active pharmaceutical ingredients revenue for the quarter was at Rs 913 crore
Subscribe To Our Newsletter & Stay Updated
